# Business Findings and Analytical Insights

## 1. Purpose

This document records the business questions, analytical observations, and practical implications explored in the Hospital Readmissions Data Analysis & Feature Engineering Pipeline.

The objective is to investigate patterns associated with hospital readmission and identify insights that may support healthcare quality improvement and operational decision-making.

## 2. Key Business Questions

The analysis is designed to explore the following questions:

1. What proportion of recorded encounters is labelled as a readmission within 30 days?
2. How does readmission status vary across patient and encounter characteristics?
3. Is medication count associated with differences in readmission patterns?
4. Does the number of recorded diagnoses vary across readmission categories?
5. What data-quality and analytical limitations should be considered when interpreting the results?

## 3. Analytical Areas

### Readmission Patterns

Examine the distribution of the dataset's readmission labels, distinguishing readmissions within 30 days from other recorded outcomes.

### Medication Burden

Explore whether encounters with different medication counts show different readmission patterns.

### Diagnosis Complexity

Compare readmission labels across groups defined by the number of diagnoses recorded.

### Data Quality and Interpretation

Consider missing values, encounter selection, excluded discharge dispositions, and the definitions used to classify readmission outcomes.

## 4. Findings Status

**Status: Results pending confirmation.**

Numerical findings and business recommendations will be added after the relevant SQL queries have been executed and their outputs reviewed.

No quantitative conclusion should be interpreted as a verified project finding until it is supported by the analysis results.

## 5. Practical Implications

The analysis may help identify patterns worth investigating further in hospital readmission data. Any observed associations should be treated as exploratory and should not automatically be interpreted as causal relationships or individual patient risk predictions.

## 6. Limitations

- The interpretation depends on the dataset's recorded readmission labels and their definitions.
- Selecting one encounter per patient may not preserve the encounter sequence needed for a robust 30-day readmission analysis.
- Exploratory groupings of medication counts and diagnosis counts are analytical choices, not validated clinical risk categories.
- Findings may not generalize to other hospitals or patient populations.
- This project is an exploratory data analysis pipeline, not a clinically validated prediction model.

## 7. Next Steps

- Execute the analytical queries and record their verified results.
- Document the key findings with supporting counts or percentages.
- Develop practical recommendations that follow from the evidence.
- Present selected findings in a Power BI dashboard.
